Key Drivers
- Strong Liquidity
- Negative Profitability
- High Cash Burn
AIAI Summary
TNGX has shifted from a broad early-stage biotech story to a high-stakes, near-term bet on vopimetostat becoming a pancreatic cancer franchise, and while the balance sheet can fund the next catalysts through 2028, the stock now hinges on durable clinical follow-through because execution missteps or dilution could quickly erase the re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Negative Profitability
- •High Cash Burn
TNGX has strong liquidity and low leverage, but persistent losses, zero latest-quarter revenue, heavy cash burn, and rich valuation make the stock fundamentally risky.
Price Behavior
Key Price Behavior Insights:
- •Breakout jump
- •Support holding
- •Resistance capped
Over the last month, TNGX broke out sharply, found support in the $28-$29 area, but finished below $32.50-$32.90 resistance with momentum cooling and volatility still elevated.
Sharp jump from $20.22 to $31.56, followed by abrupt pullbacks and reversals
Sentiment & News
Key News Insights:
- •Strong trial response
- •Large equity raise
- •Premium valuation risk
TNGX rallied on strong early vopimetostat pancreatic cancer data and then raised substantial capital, putting phase 3 progress and valuation in focus.
The stock's outlook is now driven by whether upcoming vopimetostat updates can justify the recent surge and support further upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings